JP2023040219A5 - - Google Patents

Download PDF

Info

Publication number
JP2023040219A5
JP2023040219A5 JP2023002799A JP2023002799A JP2023040219A5 JP 2023040219 A5 JP2023040219 A5 JP 2023040219A5 JP 2023002799 A JP2023002799 A JP 2023002799A JP 2023002799 A JP2023002799 A JP 2023002799A JP 2023040219 A5 JP2023040219 A5 JP 2023040219A5
Authority
JP
Japan
Prior art keywords
aav
raav
itr
encoding human
aqueous suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023002799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023040219A (ja
JP7671790B2 (ja
Filing date
Publication date
Priority claimed from JP2019547457A external-priority patent/JP7211960B2/ja
Application filed filed Critical
Publication of JP2023040219A publication Critical patent/JP2023040219A/ja
Publication of JP2023040219A5 publication Critical patent/JP2023040219A5/ja
Priority to JP2025068834A priority Critical patent/JP2025114604A/ja
Application granted granted Critical
Publication of JP7671790B2 publication Critical patent/JP7671790B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023002799A 2017-03-01 2023-01-12 眼疾患の遺伝子治療 Active JP7671790B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025068834A JP2025114604A (ja) 2017-03-01 2025-04-18 眼疾患の遺伝子治療

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762465649P 2017-03-01 2017-03-01
US62/465,649 2017-03-01
US201762469642P 2017-03-10 2017-03-10
US62/469,642 2017-03-10
JP2019547457A JP7211960B2 (ja) 2017-03-01 2018-03-01 眼疾患の遺伝子治療
PCT/US2018/020470 WO2018160849A1 (en) 2017-03-01 2018-03-01 Gene therapy for ocular disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019547457A Division JP7211960B2 (ja) 2017-03-01 2018-03-01 眼疾患の遺伝子治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025068834A Division JP2025114604A (ja) 2017-03-01 2025-04-18 眼疾患の遺伝子治療

Publications (3)

Publication Number Publication Date
JP2023040219A JP2023040219A (ja) 2023-03-22
JP2023040219A5 true JP2023040219A5 (https=) 2023-06-26
JP7671790B2 JP7671790B2 (ja) 2025-05-02

Family

ID=63370488

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019547457A Active JP7211960B2 (ja) 2017-03-01 2018-03-01 眼疾患の遺伝子治療
JP2023002799A Active JP7671790B2 (ja) 2017-03-01 2023-01-12 眼疾患の遺伝子治療
JP2025068834A Pending JP2025114604A (ja) 2017-03-01 2025-04-18 眼疾患の遺伝子治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019547457A Active JP7211960B2 (ja) 2017-03-01 2018-03-01 眼疾患の遺伝子治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025068834A Pending JP2025114604A (ja) 2017-03-01 2025-04-18 眼疾患の遺伝子治療

Country Status (11)

Country Link
US (2) US11564996B2 (https=)
EP (2) EP4656244A3 (https=)
JP (3) JP7211960B2 (https=)
KR (3) KR20230093072A (https=)
CN (2) CN110582572A (https=)
AU (2) AU2018228881B2 (https=)
BR (1) BR112019017327A2 (https=)
CA (1) CA3054136A1 (https=)
IL (2) IL314284A (https=)
RU (1) RU2019130004A (https=)
WO (1) WO2018160849A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240014102A (ko) * 2018-06-29 2024-01-31 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법
JP7640549B2 (ja) * 2019-12-12 2025-03-05 ノバルティス アーゲー 注射デバイス及び注射溶液移し替えシステム
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
US20220387627A1 (en) * 2021-06-03 2022-12-08 Hope for Hasti Vectors and gene therapy for treating cornelia de lange syndrome

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
WO1998046728A1 (en) 1997-04-14 1998-10-22 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
WO1999061643A1 (en) 1998-05-27 1999-12-02 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
ES2340230T3 (es) 1998-11-10 2010-05-31 University Of North Carolina At Chapel Hill Vectores viricos y sus procedimientos de preparacion y administracion.
PT1916258E (pt) 1999-08-09 2014-07-29 Genzyme Corp Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
US7201898B2 (en) 2000-06-01 2007-04-10 The University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
CA2442670A1 (en) * 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
NZ532635A (en) 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
EP1660970A4 (en) 2003-08-01 2007-02-14 Dna Twopointo Inc SYSTEMS AND METHODS FOR BIOPOLYMER TECHNOLOGY
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
WO2006110689A2 (en) 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
EP1777906A1 (en) 2005-06-09 2007-04-25 Matsushita Electric Industrial Co., Ltd. Amplitude error compensating apparatus and orthogonality error compensating apparatus
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
EP2091966A2 (en) * 2006-12-01 2009-08-26 Oxford BioMedica (UK) Limited Promoter construct
WO2010005533A2 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa
ES2646630T3 (es) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Lipidoides aminoalcohólicos y usos de los mismos
WO2011034947A2 (en) * 2009-09-15 2011-03-24 University Of Washington Reagents and methods for modulating cone photoreceptor activity
US20130023033A1 (en) 2010-03-29 2013-01-24 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9249425B2 (en) * 2011-05-16 2016-02-02 The Trustees Of The University Of Pennslyvania Proviral plasmids and production of recombinant adeno-associated virus
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
AU2013221212B2 (en) * 2012-02-17 2018-08-09 The Children's Hospital Of Philadelphia AAV vector compositions and methods for gene transfer to cells, organs and tissues
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
EA037448B1 (ru) 2012-06-08 2021-03-30 Этрис Гмбх Способ доставки в легкие терапевтической мрнк с pei и фармацевтическая композиция
EP2872183B1 (en) 2012-07-11 2018-09-26 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration
JP6129180B2 (ja) 2012-08-08 2017-05-17 日本パーカライジング株式会社 金属表面処理液、金属基材の表面処理方法及びそれにより得られた金属基材
US9567376B2 (en) 2013-02-08 2017-02-14 The Trustees Of The University Of Pennsylvania Enhanced AAV-mediated gene transfer for retinal therapies
ES2697249T3 (es) * 2013-03-11 2019-01-22 Fond Telethon miR-204 y miR-211 y usos de los mismos
MX384795B (es) * 2013-03-15 2025-03-14 Childrens Hospital Philadelphia Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
US9158889B2 (en) * 2013-04-26 2015-10-13 Oral4D Systems Ltd. Electronic dental charting
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
WO2015009575A1 (en) * 2013-07-16 2015-01-22 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of disorders related to cep290
KR102537394B1 (ko) * 2014-03-17 2023-05-30 애드베룸 바이오테크놀로지스, 인코포레이티드 원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
US10392622B2 (en) * 2014-08-01 2019-08-27 The Trustees Of The University Of Pennsylvania Compositions and methods for self-regulated inducible gene expression

Similar Documents

Publication Publication Date Title
JP2023040219A5 (https=)
JP2020510428A5 (https=)
Lai et al. Adenovirus and adeno-associated virus vectors
JP2019513794A5 (https=)
JP2024054426A5 (https=)
JP2021121638A5 (https=)
JP2020514286A5 (https=)
RU2018136611A (ru) Генная терапия для лечения гемофилии a
M Mitchell et al. AAV's anatomy: roadmap for optimizing vectors for translational success
JP2018537984A5 (https=)
ES2640586T3 (es) Secuencias del factor VIII
TW201629225A (zh) 第九因子基因療法
Stilwell et al. Adeno-associated virus vectors for therapeutic gene transfer
JP2020519292A5 (https=)
Yla-Herttuala et al. Improving safety of gene therapy
WO2002053703A2 (en) Aav2 vectors and methods
JPWO2020210655A5 (https=)
JP2019524090A5 (https=)
JP2024056832A5 (https=)
JP2024119830A5 (https=)
JP2018526994A5 (https=)
JP2006511212A5 (https=)
JP2021526834A5 (https=)
JP2020510433A5 (https=)
Leclerc et al. Next-generation biological vector platforms for in vivo delivery of genome editing agents